



## Total Voting Rights

**Hong Kong, Shanghai, & Florham Park, NJ — Friday, September 30, 2022:** HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at September 30, 2022, the issued share capital of HUTCHMED consisted of 864,775,340 ordinary shares of US\$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 864,775,340 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For illustrative purposes only, the 864,775,340 ordinary shares would be equivalent to 864,775,340 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 172,955,068 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

### About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,900 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has advanced 13 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: [www.hutch-med.com](http://www.hutch-med.com) or follow us on [LinkedIn](https://www.linkedin.com/company/hutchmed).

### CONTACTS

#### Investor Enquiries

Mark Lee, Senior Vice President +852 2121 8200  
Annie Cheng, Vice President +1 (973) 567 3786

#### Media Enquiries

**Americas** – Brad Miles, Solebury +1 (917) 570 7340 (Mobile) | [bmiles@soleburystrat.com](mailto:bmiles@soleburystrat.com)  
**Europe** – Ben Atwell / Alex Shaw, FTI +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) | [HUTCHMED@fticonsulting.com](mailto:HUTCHMED@fticonsulting.com)  
**Asia** – Zhou Yi, Brunswick +852 9783 6894 (Mobile) | [HUTCHMED@brunswickgroup.com](mailto:HUTCHMED@brunswickgroup.com)

#### Nominated Advisor

Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited +44 (20) 7886 2500